RHOA and autosomal dominant polycystic kidney disease: Given the persistent deregulation of RhoA signaling and actin polymerization in many models of renal ciliopathies, including ADPKD, NPHP and BBS, it would be reasonable to test Fasudil in human trials to treat ciliopathies, e.g., ADPKD or NPHP.